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Abstract: The calpain inhibitor MDL-28710 blocks the early local pro-inflammatory 
cytokine gene expression in mice after chronic constriction nerve injury (CCI). One-
hundred-thirteen wild type mice of C57Bl/6J background received CCI of the right sciatic 
nerve. Mechanical paw withdrawal thresholds and thermal withdrawal latencies were 
investigated at baseline and at 1, 3, and 7 days after CCI. Three application regimens were 
used for MDL-28170: a) single injection 40 min before CCI; b) serial injections of MDL-
28170 40 min before and up to day three after CCI; c) sustained application via 
intraperitoneal osmotic pumps. The control animals received the vehicle DMSO/PEG 400. 
The tolerable dose of MDL-28170 for mice was 30 mg/kg body weight, higher doses were 
lethal within the first hours after application. Mechanical withdrawal thresholds and 
thermal withdrawal latencies were reduced after CCI and did not normalize after single or 
serial injections, nor with application of MDL-28170 via osmotic pumps. Although the 
calpain inhibitor MDL-28170 inhibits the early local cytokine upregulation in the sciatic 
nerve after CCI, pain behavior is not altered. This finding implies that local cytokine 
upregulation after nerve injury alone is only one factor in the induction and maintenance of 
neuropathic pain. 
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Introduction  
Nerve injury in mice is associated with pain behavior and is paralleled by an increase in local 
cytokine gene expression. Chronic constriction nerve injury (CCI) is a frequently used neuropathic 
pain model, which leads to an early increase in local gene expression of the pro-inflammatory 
cytokines tumor necrosis factor-alpha (TNF) and interleukin (IL-)1β in the lesioned sciatic nerve 
already within the first hour [1]. Nerve injury results in cellular calcium influx, which in turn triggers 
downstream mediators and enzyme systems like the caspases and calpains. Calpains are a family of 
calcium dependent cysteine proteases and are involved in cellular processes like cytoskeletal protein 
cleavage, apoptosis, cell proliferation and differentiation, and synaptic plasticity [2–5]. Calpains are 
ubiquitously expressed and act within the very first hours after nerve injury; physiologic levels are 
reached within few hours [6]. Furthermore, calpains trigger the expression of mediators of Wallerian 
degeneration like IL-1β. In turn, the inhibition of calpains protects axons from trauma induced damage 
and reduces pain [7,8]. Thus, calpains may be among the early triggers of neuropathic pain.  
MDL-28170 (carbobenzylzoxy-Val-Phe-H) is a central nervous system penetrating calpain inhibitor 
(Figure 1) that passes the blood–brain barrier and inhibits brain cysteine protease activity after 
systemic application. Kunz et al. described anti-inflammatory and analgesic effects of MDL-28170 in 
the zymosan-induced paw inflammation model in rats [7]. We previously showed that the systemic 
pre-lesional application of the calpain inhibitor MDL-28170 attenuates the early local pro-
inflammatory cytokine response after CCI [1]. 
 
Figure 1. Chemical structure of MDL 28,170 (N-benzyloxycarbonylvalylphenylalaninal). 
 
Results and Discussion 
MDL-28170 dose in mice 
Following the manufacturer`s (Calbiochem, Schwalbach, Germany) instructions we first used 
dimethylsulfoxide (DMSO) to dissolve MDL-28170 and in control mice, however, this substance in 
combination with MDL-28170 was not well tolerated and the majority of the experimental animals 
died within few hours after injection. We then used DMSO/PEG 400 (1:1) instead of DMSO alone 
(personal communication with E. Niederberger, Pharmazentrum Frankfurt, Institut für Klinische 
Pharmakologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Germany), which was 
better tolerated by the mice. We found that a dose of 30 mg/kg body weight per intraperitoneal (i.p.) 
injection was well tolerated by the mice. 
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MDL-28170 does not normalize paw withdrawal latencies and thresholds after CCI  
After CCI mice developed reduced paw withdrawal latencies and thresholds (Figure 2). The 
application of MDL-28170 40 min before and immediately after surgery did not prevent the 
development of pain behavior in mice at day 3 and day 7 (Figure 2a, b). The injection of vehicle 
(DMSO/PEG 400) had no effect on pain behavior.  
Figure 2. Paw withdrawal thresholds to mechanical stimuli (a, c, e) and paw withdrawal 
latencies to thermal stimuli (b, d, f) in mice after chronic constriction injury (CCI) and 
different application regimes of MDL-28170. 
 
 
a, b: Injection of MDL-28170 i.p. once 40 min before CCI (30 mg/kg body weight). c, d: Injection 
of MDL-28170 i.p. 40 min before CCI and 4 times daily for the following 3 days (30 mg/kg body 
weight per injection). e, f: Injection of MDL-28170 i.p. 40 min before CCI and sustained 
application via ALZET osmotic mini pumps up to for 3 days after CCI. The control group received 
DMSO-PEG 400 instead. The application of MDL-28170 did not avoid, damp or delay neuropathic 
pain behaviour in mice after nerve injury by CCI 
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To achieve more consistent levels of MDL-28170 in the organism we injected the animals four 
times a day for 3 days, starting with an injection 40 min before CCI. Each injection consisted of 30 
mg/kg body weight. Again, the induction of pain behavior was not delayed or reduced (Figure 2c, d).  
We then implanted ALZET mini pumps filled with MDL-28170 immediately after CCI for 
sustained MDL-28170 application and tested the mechanical and thermal withdrawal thresholds and 
latencies. In this experiment no normalization was found for mechanical withdrawal thresholds after 
CCI and under MDL-28170 tretment (Figure 2e); however, a trend was found for a delay in reduction 
of paw withdrawal latencies in the MDL-28170 treated mice (Figure 2f; n.s.). At day 7 the MDL-
28170 and the DMSO/PEG 400 group showed reduced withdrawal latencies. 
MDL-28170 does not changeTNF gene expression in the central nervous tissue of mice after CCI 
To investigate if the application of MDL-28170 changes pro-inflammatory cytokine expression in 
the central nervous system of mice after CCI we analyzed the mRNA expression of TNF in cortex, 
hippocampus, hypothalamus, thalamus, and spinal cord of mice 1h after CCI. No difference was found 
for the expression of TNF in these tissues compared to naïve wildtype mice (Figure 3a-e).  
Figure 3. Relative gene expression of TNF in mouse a) cortex, b) hippocampus, c) 
hypothalamus, d) thalamus, e) spinal cord 1 hour after CCI and after application of MDL-
28170 or DMSO.  
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In summary, our results show: 1) that the calpain inhibitor MDL-28170 in the doses and types of 
application used here is not capable of preventing, reducing or delaying neuropathic pain behaviour in 
mice after nerve injury by CCI; 2) that MDL-28170 is poorly tolerated by mice; 3) that although 
MDL-28170 attenuates the local pro-inflammatory response [1,7] this alone seems not sufficient to 
avoid pain behavior upon mechanical and thermal stimuli.  
MDL-28170 is mainly used in in vitro experiments (for example [9–11]). In vivo experiments were 
mostly performed in rats [7,12–16]. A literature search (PubMed, through December 2009) revealed 
that only in few studies MDL-28170 was applied in mice [1,17–20]. In our own previous studies we 
injected MDL-28170 as a single application i.p. 40 min before CCI at a dose of 30 mg/kg body weight 
and showed that the early upregulation of local TNF and IL-1β gene expression in injured sciatic nerve 
one hour after CCI was attenuated. Mice were sacrificed one hour after CCI [1,17]. In the study by 
Crocker et al. the local and sustained application of MDL-28170 via Alzet osmotic mini pumps in a 
mouse model of Parkinson`s disease abolished locomotor deficits and markers of striatal postsynaptic 
activity were normalized. The osmotic pumps were filled with 160 µM MDL-28170 and were 
implanted into the right lateral ventricle of mice; the animals were sacrificed after three weeks [18]. In 
the study of Wang and collegues MDL-28170 was injected i.p. once in a dosage of 30 mg/kg body 
weight and the protective effect against thioacetamide-induced acute liver failure was investigated in 
the “surviving mice” after three days [20]. In mice deficient of cardiotrophin-1 (a member of the IL-6 
family with hepatoprotective effects) MDL-28170 injection protected against Fas-induced liver injury 
[19]. The treatment regime was MDL-28170 60 µg/g body weight 1 hour after the injection of the 
agonistic anti-Fas monoclonal antibody Jo-2; the animals were monitored up to 30 hours.  
The reported short survival times in these studies may indicate that MDL-28170 is not very well 
tolerated by mice when administered systemically. The effects of MDL-28170 have been examined in 
several animal studies also in rats or gerbils. On the field of ischemic stroke MDL-28170 was applied 
immediately after hypoxic exposure in neonatal rats (24 mg/kg; i.p. as an initial dose, followed by  
12 mg/kg every 4 hours for a total dose of 60 mg/kg over 12 hours after ischemic brain lesion). The 
animals were sacrificed 24 hours after injury. In this study MDL 28170 decreased the number of 
necrotic and apoptotic cells in distinct brain areas [15]. In one study using a gerbil model of global 
cerebral ischemia MDL-28170 was injected i.p. at a dose of 50 mg/kg body weight at four time points 
after ischemia starting 0.5 and 3 h after reperfusion. MDL-28170 protected cortical neurons from 
ischemic damage even if the treatment was delayed until 3 hours after reperfusion [21].  
MDL-28170 had neuroprotective effects in a rat model of fluid percussion injury of the brain with a 
therapeutic time window for up to 4 hours after a single administration of MDL-28170 post injury [12]. 
In a rat model of contusive spinal cord injury the combined application of MDL-28170 intravenously 
and daily i.p. resulted in improvement of functional and pathological outcome measures; rats were 
investigated up to day 42 after injury [16]. Similarly, intravenous injection of 10 mg/kg body weight 
MDL-28170 after injury for 1 week every 24 hours prevented neuronal cell death and improved motor 
disturbance after compression-induced spinal cord injury in rats [13]. Buki et al. showed that the 
single-dose pre-injury administration of MDL-28170 into the tail vein of rats 30 min before injury  
(30 mg/kg body weight) attenuates traumatically induced axonal injury [14]. Rats were sacrificed 120 
min after injury. In another study the neuroprotective effect of MDL-28170 was investigated in a rat 
model of status epilepticus [22]. MDL-28170 was applied i.p. in a dose of 50 mg/kg body weight 30 
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min before and 1 hour after pilocarpine injection (i.e., induction of seizure). Rats were sacrificed 3 
days after seizures and was shown, that MDL-28170 partially attenuated neuronal death in the  
hippocampus [22].  
The only study investigating the effect of MDL-28170 on pain behavior was performed by Kunz 
and collegues [7]. In the zymosan-induced paw inflammation model of rats MDL-28170 was injected 
i.p. 20 min before zymosan treatment (12.5 mg/kg or 25 mg/kg) or was given peridurally at a dose of 1 
mg/kg body weight [7]. Drug treatment in any regime normalized paw withdrawal latencies. Animals 
were examined up to 96 hours after MDL-28170 injection.  
In our study we did not achieve normalization of paw withdrawal latencies and thresholds after CCI 
in mice using three different treatment regimes with MDL-28170. Although MDL-28170 attenuates 
the local increase in TNF and IL-1β gene expression in the sciatic nerve [1], this alone seems not 
sufficient to attenuate pain behavior in a neuropathic model. This finding may be due to the fact that 
nerve lesion leads to a wide range of changes in the gene expression of different cytokines and their 
interactions. There are some limitations to our study. We have not investigated the gene expression of 
TNF and IL-1β at later time points and under the different treatment regimens. Thus, it is possible, that 
MDL-28170 only has a very early effect on TNF and IL-1β gene expression (i.e., within the first hour 
after nerve lesion), but does not hinder cytokine gene expression at later time points. Since the earliest 
time point for reproducible behavioral testing in mice after CCI surgery at day 3, we cannot exclude 
that the local cytokine response might have increased by then. Furthermore, the dose applied may not 
have been sufficient. However, higher doses were not tolerable. Other substances might be used as 
vehicles instead of DMSO alone or DMSO/PEG 400 to dissolve MDL-28170, possibly with better 
tolerability (e.g. Krebs` Ringer solution [18], 0.6% carboxymethyl cellulose [21], peanut oil [15]). The 
use of normal saline is inadequate [22], since MDL-28170 does not dissolve in solvents on water basis. 
One has to keep in mind that we investigated the effect of MDL-28170 only after CCI - a neuropathic 
pain model. Given the results by Kunz et al. [7] the substance may be more effective in inflammatory 
pain models. 
Experimental 
Animals 
Eight to ten weeks old female wild type mice (n = 113; 18-23 g body weight) of C57Bl/6J 
background were used. Mice were purchased from Charles River Laboratories (Sulzfeld, Germany) 
and were held at the animal facilities of the Department of Neurology of the University of Würzburg 
under standard conditions with food and water access ad libitum. All experiments were approved by 
the Bavarian State authorities. 
Surgery  
Animals received a CCI at the right sciatic nerve followed the original description [23] with slight 
modifications [24]. Briefly, the sciatic nerve was exposed under intraperitoneal (i.p.) barbiturate 
narcosis (Narcoren®, 50 mg/kg body weight). Three ligatures (7-0 prolene) were placed around the 
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nerve proximal to the trifurcation with a distance of one mm between each ligature. The ligatures were 
loosely tied until a short flick of the ipsilateral hind limb occurred.  
Behavioral testing 
Mechanical paw withdrawal thresholds (von Frey test) and thermal paw withdrawal latencies were 
investigated at baseline (i.e., once a day on two days before CCI) and at days 1, 3, and 7 after CCI. The 
investigator was not aware of the pharmacological treatment the animals had received. The von Frey 
test based on the up-and-down-method as previously described [25]. Animals were placed in 
Plexiglass cages on a wire mesh and the plantar surface of the hind paws was touched with a von Frey 
filament. The measurements started at a hair value of 0.69 g. When the animal withdrew its hindpaw 
upon application of mild pressure the next finer von Frey filament was used. If the animal did not react 
to the stimulus, the next stronger von Frey filament was used. Each hind paw was tested three times. 
The 50% withdrawal threshold (i.e., force of the von-Frey hair to which an animal reacts in 50% of the 
administrations) was recorded. The thermal paw withdrawal latencies were investigated applying the 
method of Hargreaves [26] and using a standard Ugo Basile Algesiometer (Comerio, Italy). Mice were 
placed on a glass surface surrounded by Plexiglass cages. A radiant heat source was positioned under 
one hind paw and the time until a withdrawal reaction occurred was measured. The time limit for heat 
application was 15 sec at maximum to avoid burning damage. Each hind paw was tested three times 
with a minimum interval of 2 min between the measurements to avoid habituation. The investigator 
was blinded as to the treatment of the mice.  
Pharmacological treatment 
We used the calpain inhibitor III MDL-28170 (Calbiochem, Schwalbach, Germany) for our 
experiments. MDL-28170 was dissolved in DMSO/PEG 400 (1:1). DMSO/PEG 400 was used instead 
of DMSO alone to reduce mouse lethalty after injection. Treatment was applied by an investigator 
blinded to the substance.  
Treatment regimes and dosages 
Single injection i.p.: We previously showed that the single shot i.p. treatment of mice 40 min before 
CCI using MDL-28170 inhibits early upregulation of pro-inflammatory cytokine gene expression in 
the sciatic nerve [1]. To investigate if this single shot injection also reduces pain behavior after CCI we 
treated mice with 30 mg/kg body weight i.p. 40 min. before CCI. Control animals received equivalent 
volumes of DMSO/PEG 400 (1:1).  
Serial injections i.p.: To increase the amount of MDL-28170 and prolong its possible analgesic 
effects we treated mice 40 min. before CCI and four times per day for three days after CCI with  
30 mg/kg body weight each. The cumulative dose per kg body weight of MDL-28170 applied per 
mouse was 390 mg.  
Osmotic pump: To achieve sustained drug release we injected 30 mg/kg body weight per mice i.p. 
40 min before CCI and implanted Alzet osmotic pumps (model 1003D, Alzet, USA) i.p. immediately 
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after CCI. Pumps for 3 days of drug release were used and the cumulative dose of MDL-28170 applied 
per kg body weight per mouse was 390 mg.  
Relative gene expressin of TNF in the central nervous system under MDL-28170 treatment 
In previous pilot experiments we investigated the relative gene expressin of TNF in the central 
nervous system of mice after CCI. Ten wildtype mice of C57Bl/6J background were treated with 
MDL-28170 or DMSO 40 min before CCI at a dosage of 30 mg/kg body weight. One hour after CCI 
cortex, hippocampus, hypothalamus, thalamus, and the spinal cord were dissected and immediately 
shock-frozen in liquid nitrogen before further processing. RNA extraction, reverse transcription and 
quantitative real-time PCR (qRT-PCR) were performed as previously described [1].  
Conclusions  
CCI leads to an early increase in local pro-inflammatory cytokine expression associated with pain 
behavior in mice. The calpain system is involved in triggering cytokine production in the very early 
few hours after nerve injury and may be of key importance also in the induction of pain behavior. The 
application of the calpain inhibitor MDL-28170 has proven to attenuate the early pro-inflammatory 
response and to improve thermal latencies in rats, however, the i.p. application of MDL-28170 (single 
injection, multiple injections, osmotic pump) before and after CCI does not normalize withdrawal 
latencies and thresholds in mice after CCI. MDL-28170 is of limited importance in the investigation of 
neuropathic pain in mice after CCI.  
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